Portal Study (Protocol number: GR40549)
A 144 week extension study that will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in patients with neovascular age-related macular degeneration (nAMD) who have either completed Phase IIIb Study WR42221 (Velodrome), or completed Week 24 visit in Study WR42221 but were not eligible to be randomized in WR42221.
ClinicalTrials.gov Identifier: NCT03683251
Principal Investigator: Dr Chen, Fred
For further information about this study, you may visit Clinical Trial Registry:
https://clinicaltrials.gov/ct2/show/NCT03683251?term=velodrome&draw=1&rank=2
Or contact the Lions Eye Institute Clinical Trials Office telephone (08) 9381 0750 or email lionsvisiontrials@lei.org.au
